(Q36804054)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Cryptococcus neoformans

1 reference

inferred from title

author

Nathan Paul Wiederhold

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Brian L Wickes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

6

Thomas F Patterson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

George R Thompson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Annette W Fothergill

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ana C Vallor

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

16 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

number of pages

3

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

2959-2961

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

New and emerging treatments for fungal infections

9 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493144

Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559645

12 December 2020

inferred from PubMed ID database lookup

Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559645

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.00646-08

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18559645%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference